HIV controllers (HICs) are rare persons living with HIV who spontaneously maintain low or undetectable viremia. Low-grade chronic inflammation persisting in this population could lead to higher rates of non-AIDS defining events (nADEs) than in patients who achieve low or undetectable viremia on antiretroviral therapy (ART).
From the ongoing multicenter ANRS CODEX cohort, we enrolled 315 HICs with a known HIV-1 infection ≥5 years, with at least 5 consecutive viral loads (VL) below 400 HIV RNA copies/mL in the absence of ART. The ongoing multicenter ANRS PRIMO Cohort enrolls HIV-1 infected patients diagnosed during primary infection (≤3 months). From this latter cohort, we included 328 patients who initiated ART ≤1 month after the diagnosis, with undetectable VL ≤12 months following ART initiation and for at least 5 years (“ART-subjects”). Incidence rates (IR) of first nADEs, i.e. malignancies, cardiovascular, pulmonary, hepatic, psychiatric or bone events were compared between HICs and ART-subjects; potential determinants were assessed by using Cox regression models.
The most common events observed in the 2 cohorts were non-AIDS related infections (36.9%), psychiatric (17.2%), cardiovascular (6.8%), and malignancies (6.1%), with no statistically significant differences in distribution between the 2 cohorts. Two and 4 non-AIDS related deaths were observed among HICs and ART subjects, respectively. All-cause nADEs incidence rates were 2.8 per 100 person-years (py) and 5.3 per 100 py among HICs and ART subjects, respectively (Hazards Ratio HR=0.53 [95%Confidence Interval (95%CI), 0.40-0.71]. After adjustment for the cohort, demographic and immunological characteristics, the only other factor associated with all cause nADEs occurrence was age 36-43 (vs. 18-29) years at beginning of control (HR=1.56 [95%CI, 1.06-2.30]). Baseline CD4 T-cell count or nadir, CD4/CD8 ratio, history of viral blips, HBV/HCV co-infection and tobacco use, were not associated with an increased risk of nADEs.
HICs, defined on the basis of ≥5-year period of spontaneous viral control, experienced two times less nADEs than virologically suppressed patients on ART. Age was the only other factor independently associated with nADEs occurrence, irrespective of immune or virologic parameters. These results do not argue in favor of expanding the indication for ART for HICs subjects but rather a case-by-case approach considering clinical outcomes such as nADEs besides immune activation.